If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Exercise of Options

8 Mar 2023 14:45

RNS Number : 3363S
Plant Health Care PLC
08 March 2023
 

 

Plant Health Care plc

 

("Plant Health Care" or "the Company")

 

Exercise of Options Director / PDMR Shareholding

Plant Health Care, a leading provider of novel patent-protected biological products to global agricultural markets, announces that, on 7 March 2023, a total of 3,547,070 new Ordinary Shares (the 'New Ordinary Shares') were issued pursuant to the exercise of options by employees under the Company's US Sub Plan of the 2017 Employee Share Option Plan (the 'Plan').  

On 10 March 2022, the Company awarded 3,547,070 Options (the 'Options') to employees with an exercise price of 1p per ordinary share in the Company (the 'Ordinary Shares'). Senior employees and Executive Directors were required to accept these Options as a substitute for 50% of their annual cash bonus opportunity for 2022. Under the Plan the Options vest, inter alia, on the achievement of the performance targets during 2022 as set out in the table below. 

 

 

Goal

Summary of targets

1

Financials

Revenue of $ 10.6 million, gross margin of $6.7 million and LBITDA of $3.7 million.

2

Commercial

Achieve on-ground sales targets in key markets.

3

Commercial

Secure at least two significant new distribution agreements for Harpin or PREtec in row crop markets

4.

Commercial

Step up engagement by newly appointed CEO with the investor community.

 

Following review by the Board of Plant Health Care, it has been determined that the performance criteria were met in full. Subsequently, all option holders have decided to exercise their Options in full prior to the IRS requirement to exercise prior to 15 March 2023.

Of the Options exercised, Jeffrey Tweedy, Chief Executive Officer, and Jeffrey Hovey, Chief Financial Officer, have each exercised 1,237,122 and 445,365 Options retrospectively. Mr Tweedy has sold 305,000 Ordinary Shares issued and Mr Hovey has sold 107,000 Ordinary Shares issued to cover their taxes due.

Following these transactions, Jeffrey Tweedy is interested in 1,888,548 Ordinary Shares representing 0.61% of the issued share capital of the Company and Jeffrey Hovey is interested in 990,061 Ordinary Shares representing 0.32% of the issued share capital of the Company.

Application for admission of the New Ordinary Shares to trading on AIM ('Admission') has been made and dealings in the New Ordinary Shares are expected to commence on or around 8.00 a.m. on 10 March 2023. The New Ordinary Shares will rank pari-passu with the Company's existing issued Ordinary Shares.

 

Total voting rights

 

Following the issue of the New Ordinary Shares, the Company has 310,484,552 Ordinary Shares in issue with no shares held in treasury. This is the total number of voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Enquiries

 

Plant Health Care plc

+1 919 926 1600

Jeffrey Tweedy - Chief Executive Officer

Jeffrey Hovey - Chief Financial Officer

Cenkos Securities plc - Nomad and Joint Broker

Neil McDonald / Peter Lynch

 

+44 (0)131 220 9771

SEC Newgate - Financial Communications

Robin Tozer / Richard Bicknell / George Esmond

+44 (0) 7540 10666

phc@secnewgate.co.uk

Company website: www.planthealthcare.com

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jeffrey Tweedy

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Plant Health Care plc

b)

LEI

 

213800KBQPJZ2FM8QH27

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 1p each GB00B01JC540

b)

Nature of the transaction

1. Issue of Shares following exercise of options

2. Sale of Shares following exercise of options.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1) £0.01

2) £0.1105

1) 1,237,122

2) 305,000

d)

Aggregated information

-

Aggregated volume

-

Price

 

N/A

e)

Date of the transaction

1) 07.03.2023

2) 08.03.2023

f)

Place of the transaction

AIM, London Stock Exchange

 

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jeffrey Hovey

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Plant Health Care plc

b)

LEI

 

213800KBQPJZ2FM8QH27

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 1p each GB00B01JC540

b)

Nature of the transaction

1. Issue of Shares following exercise of options

2. Sale of Shares following exercise of options

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1) £0.01

2) £0.1105

1) 445,365

2) 107,000

d)

Aggregated information

-

Aggregated volume

-

Price

 

N/A

 

e)

Date of the transaction

1) 07.03.2023

2) 08.03.2023

f)

Place of the transaction

AIM, London Stock Exchange

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEBSGDXDSGDGXI
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.